NEW YORK (GenomeWeb News) — The Immune Tolerance Institute and the David H. Murdock Research Institute have established a Kannapolis, NC, research center designed to speed up discovery and development of treatments for people with a broad range of immune system-related conditions.
The Center for Critical Path Research in Immunology will operate at the Murdock Institute's facility within the North Carolina Research Campus, a $1.5 billion, 350-acre laboratory/office site developed by Murdock — a real estate and food magnate who is chairman of Dole Foods — to accommodate health, nutrition, and agricultural research.
CCPRI said in a statement that it will integrate "genomic, cellular, proteomic and bioinformatics technology platforms to discover and develop novel biomarkers," as well as "match patients with therapies that will provide them the greatest benefit."
The new research center said its goals are "to accelerate the translation of basic discoveries into medical practice, and to become a major resource for a range of academic and industry partners."
Based in Menlo Park, Calif., ITI is a non-profit corporation founded in partnership with the University of California, San Francisco, to translate scientific discoveries into new therapies for diseases related to the human immune system — including autoimmune diseases, allergy, asthma, cancer, and cardiovascular and infectious diseases.
The announcement of CCPRI, made earlier today, is the second in consecutive days concerning new users for the North Carolina Research Campus. Yesterday, the campus announced that General Mills will establish a presence there to carry out research into whole grains and vegetables.